INBX · Inhibrx Biosciences, Inc. · Executive Compensation
$87.75
-2.85 (-3.14%)
At close · Nov 12
Return incl. dividend (before tax)
Market Cap
$1.29B
Shares
14.72M
Volume · Nov 12
226.49K
Avg daily vol (3M)
305.28K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark P. Lappe | Chief Executive Officer and Chairman of the Board of Directors | $2,892,473 |
| David J. Matly | M.B.A. President | $1,435,940 |
| Kelly D. Deck | C.P.A. Chief Financial Officer | $923,696 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark P. Lappe | Chief Executive Officer and Chairman of the Board of Directors | $4,691,783 |
| Kelly D. Deck | C.P.A. Chief Financial Officer | $4,267,254 |
| Brendan P. Eckelman | Former Chief Scientific Officer | $2,627,592 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark P. Lappe | Chief Executive Officer and Chairman of the Board of Directors | $2,802,021 |
| Brendan P. Eckelman | Former Chief Scientific Officer | $1,451,958 |
| Kelly D. Deck | C.P.A. Chief Financial Officer | $1,148,899 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brendan P. Eckelman, Ph.D. | EVP, Chief Scientific Officer | Resigned | 2025-04-01 |
| David J. Matly, M.B.A. | President | Appointed | 2025-04-01 |
Leadership
- Mark P. Lappe CEO, Board Member
- Kelly D. Deck CFO
- Douglas G. Forsyth Board Member
- Jon Faiz Kayyem Board Member
- Kimberly Manhard Board Member
- Kristiina Vuori Board Member
Key facts
CIK
2007919
CUSIP
45720N103
13F (30d)
88 filings
84 filers
Visit website
Investor relations